However, the same plan was carried out for all the VHL patients according to the current surveillance recommendations, regardless of the fact that VHL disease demonstrates obvious phenotypic heterogeneity, which resulted in diagnostic and therapeutic delay of patients with early onset age. This evidence concerns the gene VHL and von Hippel-Lindau disease.